Plasma Neuro fi lament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
暂无分享,去创建一个
Sheng-Yang M. Goh | A. Toga | L. Petrucelli | B. Dickerson | B. Boeve | K. Kantarci | M. Grossman | D. Knopman | D. Kaufer | J. Kramer | A. Danek | S. Weintraub | R. Vandenberghe | S. Sorbi | T. Foroud | G. Coppola | D. Galimberti | M. Bocchetta | A. Boxer | A. Karydas | J. Rohrer | J. Kornak | D. Cash | E. Huey | I. Litvan | H. Heuer | C. Graff | G. Hsiung | A. Jeromin | N. Graff-Radford | D. Irwin | K. Domoto-Reilly | R. Laforce | E. Roberson | I. Mackenzie | M. Tartaglia | B. Borroni | M. Masellis | F. Tagliavini | I. Santana | R. Sánchez-Valle | M. Synofzik | C. Onyike | A. Kieloch | J. Swieten | A. Staffaroni | S. Ducharme | D. Kerwin | Linan Song | A. Gerhard | H. Rosen | N. Ghoshal | Rajeev Sivasankaran | A. Mendonça | E. Ramos | J. Fong | R. Pearlman | Joanne B. Taylor | J. Levin | Bruce L Miller | Y. Cobigo | C. Heller | R. Convery | F. Moreno | A. Pantelyat | Y. Bordelon | P. Ljubenkov | C. Butler | J. Rojas | B. Appleby | M. Otto | Georgia Peakman | E. Todd | A. Wolf | L. Russell | I. Swift | C. Greaves | M. Valentin | M. Foiani | L. Mitic | Danielle L. Graham | Mario F. Mendez | J. Czerkowicz | E. Finger | J. Rowe | Carolin Heller | Imogen Swift | Christopher R. Butler | R. Rademakers | Ping Wang | Eliseo Veras | D. Hanlon | Arvind Khinikar | Weiping Chen | Bruce L. Miller
[1] G. Frisoni,et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[2] David T. Jones,et al. Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[3] A. Toga,et al. Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[4] David T. Jones,et al. Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[5] David T. Jones,et al. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology , 2019, Alzheimer's & Dementia.
[6] David T. Jones,et al. Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration , 2019, Alzheimer's & Dementia.
[7] A. Ludolph,et al. CNS phenotype in X linked Charcot- Marie-Tooth disease , 2018, Journal of Neurology Neurosurgery & Psychiatry.
[8] D. Stuss,et al. Therapeutic trial design for frontotemporal dementia and related disorders , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[9] A. Fagan,et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory , 2018, Annals of clinical and translational neurology.
[10] K. Blennow,et al. Biomarkers for Alzheimer's disease: current status and prospects for the future , 2018, Journal of internal medicine.
[11] F. Ferris,et al. Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases , 2017, Investigative ophthalmology & visual science.
[12] Yong Ji,et al. The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China , 2017, Aging & mental health.
[13] Anders M. Dale,et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia , 2017, Acta Neuropathologica.
[14] M. Jorge Cardoso,et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia , 2016, Neurology.
[15] S. Ourselin,et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia , 2016, Annals of clinical and translational neurology.
[16] Veronica Redaelli,et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis , 2015, The Lancet Neurology.
[17] L. Grinberg,et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration , 2014, Annals of neurology.
[18] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[19] Bruce L. Miller,et al. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia , 2011, Neuropsychologia.
[20] M. Hutton,et al. The genetics of frontotemporal dementia. , 2007, Neurologic clinics.
[21] S. Targum,et al. The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).
[22] John Ashburner,et al. A tensor based morphometry study of longitudinal gray matter contraction in FTD , 2007, NeuroImage.
[23] S. Melquist,et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.
[24] K. Blennow,et al. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD , 2000, Neurology.
[25] Bonnet Am. [The Unified Parkinson's Disease Rating Scale]. , 2000 .
[26] Ronald C. Petersen,et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.
[27] C. Wikkelsø,et al. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.
[28] T. Kurosaki,et al. Measurement of functional activities in older adults in the community. , 1982, Journal of gerontology.
[29] R. Reitan. Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .
[30] A. Minagar. Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab , 2011 .
[31] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[32] Z. Schwab,et al. Projection technique for evaluating surgery in Parkinson’s disease , 1969 .